Should I Buy PALI? PALI 2026 Analysis

Should You Buy Palisade Bio Inc (PALI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.610

1 Day change

-3.59%

52 Week Range

2.640

Analysis Updated At

2026/01/26

Palisade Bio Inc (PALI) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has promising analyst ratings and potential catalysts in its pipeline, its financial performance is weak, and there are no strong technical or trading signals to justify immediate action. Holding off for more clarity on financial improvement or pipeline results is recommended.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 52.29, suggesting no clear overbought or oversold conditions. Moving averages are converging, showing no strong trend. The stock is trading near its pivot level of 1.84, with resistance at 1.991 and support at 1.689.

Options Data

Positive Catalysts

The company's lead drug, PALI-2108, has shown promising clinical results and has upcoming pipeline catalysts within the next 12-18 months.

Neutral/Negative Catalysts

There are no recent news updates or significant trading trends from hedge funds, insiders, or Congress.

Financial Performance

In Q3 2025, the company reported no revenue growth, a net income loss of -$2.87M (down -17.75% YoY), and an EPS drop of -83.62% YoY. Gross margin remains at 0%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are optimistic about the stock, with multiple buy ratings and price targets ranging from $7 to $25. Analysts highlight the potential of PALI-2108 as a first-in-class treatment for inflammatory bowel disease and its promising clinical results.

4 Analyst Rating

Wall Street analysts forecast PALI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PALI is 13 USD with a low forecast of 7 USD and a high forecast of 25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.670

Low

Averages

High

Current: 1.670

Low

Averages

High

B. Riley

initiated

AI Analysis

2026-01-09

Reason

B. Riley

Price Target

AI Analysis

2026-01-09

initiated

Reason

B. Riley initiated coverage of Palisade Bio with a Buy rating and $7 price target. The company is developing PALI-2108, a pro-drug PDE4 B/D inhibitor, incorporating tissue-specific activation for the treatment of ulcerative colitis and fibrostenotic Crohn's disease, the analyst tells investors in a research note. Riley views PALI-2108 as an attractive option in the inflammatory and fibrotic disease space.

Clear Street

Kaveri Pohlman

Buy

initiated

$12

2025-12-29

Reason

Clear Street

Kaveri Pohlman

Price Target

$12

2025-12-29

initiated

Buy

Reason

Clear Street analyst Kaveri Pohlman initiated coverage of Palisade Bio with a Buy rating and $12 price target. The firm says the company's lead asset PALI-2108, a first-in-class oral PDE4-inhibitor prodrug for inflammatory bowel disease, has shown "compelling biology," including 100% clinical response and 40% clinical remission in ulcerative colitis. The shares offer an attractive risk/reward into multiple pipeline catalysts over the next 12-18 months, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PALI

Unlock Now

PALI Should I Buy

PALI Should I Buy

Should You Buy Palisade Bio Inc (PALI) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch